Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility

• Published in: Journal of gastroenterology 2020-11, Vol.55 (11), p.1054-1061
• Main Authors: Okubo, Hidetaka, Akiyama, Junichi, Kobayakawa, Masao, Kawazoe, Megumi, Mishima, Saori, Takasaki, Yusuke, Nagata, Naoyoshi, Shimada, Takayuki, Yokoi, Chizu, Komori, Shiori, Kimura, Kana, Hisada, Yuya, Iwata, Eri, Watanabe, Kazuhiro, Yanagisawa, Naohiro, Shiroma, Sho, Shimomura, Akira, Okahara, Koki, Cho, Hourin, Uemura, Naomi
• Format: Article
• Language: English
• Subjects: Abdominal Surgery; Adult; Aged; Aged, 80 and over; Amoxicillin; Amoxicillin - administration & dosage; Amoxicillin - adverse effects; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - adverse effects; Clarithromycin; Clarithromycin - administration & dosage; Clarithromycin - adverse effects; Colorectal Surgery; Drug Resistance, Bacterial; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Gastroenterology; Health aspects; Helicobacter infections; Helicobacter Infections - drug therapy; Helicobacter Infections - microbiology; Helicobacter pylori; Helicobacter pylori - drug effects; Helicobacter pylori - isolation & purification; Hepatology; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Original Article―Alimentary Tract; Peptic ulcer; Prospective Studies; Proton Pump Inhibitors - administration & dosage; Proton Pump Inhibitors - adverse effects; Pyrroles - administration & dosage; Pyrroles - adverse effects; Stomach cancer; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Surgical Oncology; Treatment Outcome; Urea; Young Adult
• ISSN: 0944-1174; 1435-5922
• DOI: 10.1007/s00535-020-01723-6

Background Helicobacter pylori causes peptic ulcers and accounts for over 90% of gastric cancers; however, eradication rates have been declining due to antimicrobial resistance. Vonoprazan (VPZ), a potassium-competitive acid blocker, produces rapid and profound gastric acid suppression and has shown promising effects in the improvement of H. pylori eradication rates. The efficacy and safety of VPZ-based triple therapy as a first-line regimen for H. pylori eradication and its relationship with clarithromycin (CAM) susceptibility were evaluated. Methods From May 2015 to September 2017, H. pylori -infected patients who underwent esophagogastroduodenoscopy with CAM susceptibility testing were prospectively enrolled. Patients received a 7-day triple therapy regimen (VAC) of VPZ (20 mg), amoxicillin (750 mg), and CAM (200 mg) twice daily. Eradication rates, demographics, CAM susceptibility, and safety profiles were assessed. Results VAC was administered to 146 patients (median age: 63, range: 22–85 years) (60% of whom were females) who underwent CAM susceptibility testing, and 131 patients underwent 13 C-urea breath testing to evaluate eradication success. The prevalence of CAM resistance was 34.2%. The overall eradication rates of VAC in per protocol (PP) and “intention to treat” (ITT) analyses were 90.8% ( n  = 131) and 81.5% ( n  = 146), respectively. In PP analysis for CAM susceptibility, the eradication rates of VAC were comparable between CAM-sensitive (91.6%, n  = 83) and CAM-resistant (89.4%, n  = 47) strains. The corresponding rates from the ITT analysis were 80.0% ( n  = 95) and 84.0% ( n  = 50), respectively. No adverse events requiring discontinuation of VAC were observed. Conclusions CAM-resistant H. pylori was prevalent in one-third of patients in the Tokyo metropolitan area. VPZ-based triple therapy was highly effective and well-tolerated irrespective of CAM susceptibility. Therefore, it could be a valuable first-line treatment regimen for H. pylori infection.